Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Rating of “Moderate Buy” from Analysts

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) has earned a consensus rating of “Moderate Buy” from the fourteen analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and eleven have given a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $44.10.

Several equities analysts have recently weighed in on OLMA shares. Guggenheim decreased their price objective on Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating for the company in a report on Wednesday, May 13th. TD Cowen restated a “buy” rating on shares of Olema Pharmaceuticals in a report on Monday, March 9th. HC Wainwright restated a “buy” rating on shares of Olema Pharmaceuticals in a report on Friday, May 22nd. JPMorgan Chase & Co. raised their price objective on Olema Pharmaceuticals from $55.00 to $58.00 and gave the company an “overweight” rating in a report on Wednesday, March 18th. Finally, Oppenheimer restated an “outperform” rating on shares of Olema Pharmaceuticals in a report on Monday, March 9th.

Hedge Funds Weigh In On Olema Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. EverSource Wealth Advisors LLC grew its holdings in shares of Olema Pharmaceuticals by 9,476.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock valued at $31,000 after acquiring an additional 1,232 shares in the last quarter. Torren Management LLC acquired a new stake in Olema Pharmaceuticals in the 4th quarter valued at about $44,000. Russell Investments Group Ltd. acquired a new stake in Olema Pharmaceuticals in the 3rd quarter valued at about $53,000. American Century Companies Inc. acquired a new stake in Olema Pharmaceuticals in the 2nd quarter valued at about $54,000. Finally, Creative Planning acquired a new stake in Olema Pharmaceuticals in the 2nd quarter valued at about $83,000. Institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Price Performance

OLMA stock opened at $9.82 on Thursday. The stock has a 50-day moving average price of $14.17 and a two-hundred day moving average price of $20.74. The stock has a market cap of $857.78 million, a PE ratio of -4.86 and a beta of 1.98. The company has a current ratio of 10.88, a quick ratio of 10.88 and a debt-to-equity ratio of 0.01. Olema Pharmaceuticals has a 1 year low of $3.89 and a 1 year high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its earnings results on Tuesday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.52). Equities analysts forecast that Olema Pharmaceuticals will post -2.16 EPS for the current fiscal year.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.